Introduction
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the accumulation of malignant plasma cells within the bone marrow (BM). Binding of MM cells to bone marrow stromal cells (BMSC) promotes tumor cell growth, survival, and drug resistance by both MM cell-BMSC contact and triggering of cytokines secretion. 1 Among these cytokines, interleukin-6 (IL-6) produced by BMSC plays a major role on both proliferation and survival of tumor cells. [2] [3] [4] In turn, MM cells secrete vascular endothelial growth factor (VEGF), which further promotes production of IL-6 in BMSC, as well as migration and proliferation of the tumor cells. Thus VEGF is both an autocrine growth factor and trigger of IL-6-mediated paracrine MM cell growth. Recent reports have highlighted the major role of VEGF in MM pathogenesis, demonstrating that VEGF also increases micro-vessel density in the BM. [5] [6] [7] Moreover, VEGF increases bone-resorbtion by osteoclasts and inhibits maturation of dendritic cells. 8, 9 Taken together, these reports have promoted pre-clinical MM studies which confirm the promise of VEGF targeting therapies. [10] [11] [12] . Although the impact of VEGF on MM cell proliferation and migration is well documented, its role in conferring protection against apoptosis remains unknown. As reported in other hematological malignancies such as leukemia, VEGF upregulates Bcl-2 and thus protects leukemia cells against chemotherapy. 13, 14 Furthermore, among the Bcl-2 family members induced by VEGF, Katoh et al have demonstrated that Mcl-1 was critical to protect leukemia cell lines against etoposide-induced-apoptosis. 15 only.
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Myeloid-cell-leukemia 1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 family which is distinguished from other Bcl-2 family members, like Bcl-2 or Bcl -x L , by its short half-life and ability to protect cells against a large variety of cytotoxic stimuli. Moreover, Mcl-1 downregulation is a critical and pivotal checkpoint controlling mitochondrial apoptotic events, such as cytochrome c release and caspase activation. 16, 17 Recently, Opferman et al demonstrated that Mcl-1 is also required for development and maintenance of B and T lymphocytes. 18 In MM, IL-6 activates the JAK/Stat-3 pathway leading to the upregulation of
Mcl-1 expression. 19, 20 Using oligonucleotide antisense technique (ASO) induces apoptosis of MM cells. 21 22 Conversely, the anti-apoptotic effect of IL-6 is mediated 
Materials and methods

Cells and cell culture
The human MM cell lines (HMCLs) MM1s, MM1r and U266, as well as patient MM cells were maintained in RPMI 1640 medium with 2 mM L-glutamine (Mediatech, Cellgro, AK, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 10 µg streptomycin (Mediatech). Murine embryonic fibroblast cell line Mcl-1 wt/wt and
Mcl-1 /null MEFs were kindly provided by J Opferman (Howard Hughes Institute, DanaFarber Cancer Institute, Boston, MA). 18 MEFs were maintained in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 10 µg streptomycin and 2 mM L-glutamine, 2 mercapto-ethanol (Sigma) and MEM non-essential amino-acid (Gibco, Grand Island, NY). 
Isolation of patient's tumor cells
Flow cytometry and cell cycle analysis
For cell cycle analysis, DNA was stained with propidium iodide. Briefly, 1x10 6 cells were washed with 1xPBS, re-suspended in 70% ethanol, and then incubated for 30 min on ice.
After incubation, cells were washed twice with 1x PBS and re-suspended in the presence of RNase for 20 min at 37°C. After two washes in 1x PBS, cells were re-suspended in propidium iodide on ice for 20 min for cytometric analysis. Apoptotic cells were detected as a subdiploid peak, as described by Zamai et al. 29 Flow cytometry was analysed using Cytomics RXP program (Beckman Coulter).
Apoptotic MM patient cells were assayed with double staining using CD38 and Apo2.7 mAbs coupled to FITC and PE, respectively (Immunotech, Marseille, France). After staining, MM and non-MM patient cells were gated according to their CD38 expression (CD38 ++ and CD38 +/-for MM cells and non-MM cells, respectively), and apoptotic cells were assessed by Apo 2.7 expression, as previously described. 30 Thus, the percentage of apoptotic cells in each cell subset was separately measured.
Cell lysis and Western-blot
Cells were washed 2 times with 1xPBS and suspended in lysis buffer (10mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% triton X-100, 1 mM sodium vanadate, 1 mMN phenylmethyl sulfonyl fluoride and 2 mg/ml aprotinin). After 40 min on ice, lysates were cleared by centrifugation at 13 000g/min for 30 min at 4°C and were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, prior to electrophoretic transfer For To confirm the specific link between VEGF stimulation and Mcl-1 upregulation, VEGF-R was inhibited using GW654652, a pan-VEGF-R inhibitor. 12 After overnight starvation, MM1s cells were cultured for 1h in the absence or presence of various doses of GW654652, followed by culture without or with 50 ng/ml of VEGF for 6h. As shown in Figure 3c , upregulation of To confirm that cytotoxicity was due to apoptosis, cell cycle analysis was performed. 
VEGF overcomes inhibition of DNA synthesis induced by FBS starvation in MM1s cells
We next investigated whether VEGF could overcome FBS starvation in MM1s cells. MM1s cells were starved in RPMI 0.5% FBS overnight, followed by culture with or without various doses of VEGF. DNA synthesis was evaluated by 3 H-thymidine incorporation ( Figure 6 ). 
Discussion
VEGF induces angiogenesis, vasculogenesis, vasodilatation, and increases vascular
permeability. 33 Because of its ability to promote the growth of tumor vascular environment, VEGF is a major growth factor mediating tumor progression. 34 In MM, VEGF increases micro vessel density (MVD), reflecting bone marrow angiogenesis. Thus, MVD has been reported to increase during disease progression from monoclonal gammapathy of undeterminated significance (MGUS) to active MM. 5, 35, 36 In addition, a high BM MVD is an adverse prognosis factor. 37 Taken together, these reports demonstrate that VEGF, by its effects on the BM microenvironment of MM cells, is a major factor in MM progression. Like other proteins including p53, the E2F family proteins and survivin, Mcl-1 is involved not only in apoptosis but also in cell cycle regulation. [42] [43] [44] [45] Indeed, Mcl-1 is a cell cycle regulator through its interaction with proliferating cell nuclear antigen (PCNA), a cell cycle-regulatory protein essential for G1 to S phase transition. 45 We believe that Fujise's reports and our present study highlight the complexity of the role of
Mcl-1 in cell cycle regulation. As reported by Craig et al, Mcl-1 interacts with a large panel of proteins involved in cell cycle or/and apoptosis, including other Bcl-2 family members, and thus creates a "coordinated network" influencing viability, proliferation, and differentiation. 25 only.
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Because of its rapid and inducible expression, short-term effects, ability to interact with others proteins, and rapid turnover, Mcl-1 has the "parfait profil" of a protein responsive to a large spectrum of stimuli influencing differentiation, proliferation, and survival.
In conclusion, we show in the present report that VEGF protects patient MM cells against FBS starvation induced-apoptosis and that VEGF, like IL-6, is not only a growth, but also an anti-apoptotic factor. Indeed, VEGF up-regulates Mcl-1 expression in MM cells, thereby mediating, at least in part, its anti-apoptotic capacity. As further confirmation of its potent anti-apoptotic role, we also demonstrate that VEGF upregulates survivin and cIAP anti- HMCLs (MM1s, MM1r and U266) were starved overnight in RPMI 1640 with 0.5% FBS and then cultured in the absence on presence of VEGF (50 ng/ml) or IL-6 (50 ng/ml) for 6 h. Cell 
